A dipeptidyl peptidase 4 inhibitor, vildagliptin, could successfully downregulate EndoMT and reduce lung fibrosis in lipopolysaccharides-induced lung injury [14]. The gene discussed is DPP4; the disease is pulmonary fibrosis.